We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

In need of medication

14 June 2007 By Pierre Briancon

The French drug maker lost E6bn, or 6.5%, of its market cap after a panel said its proposed antiobesity drug is too risky to recommend. It looks like a lost blockbuster. With a weak strategy and two big shareholders on the way out, Sanofi could become an acquisition target. The French drug maker lost E7bn, or 8%, of its market cap after a panel said its proposed antiobesity drug is too risky to recommend.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)